On May 29, 2018 Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, reported that Isaac Ciechanover, M.D., the Company’s President and Chief Executive Officer, will participate at two upcoming investor conferences in June (Press release, Atara Biotherapeutics, 29 29, 2018, View Source [SID1234526936]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2018 Global Healthcare Conference
Company Presentation: Tuesday, June 5, 2018 at 11:00 a.m. ET
Grand Hyatt in New York, NY

Goldman Sachs 39th Annual Global Healthcare Conference
Fireside Chat: Tuesday, June 12, 2018 at 1:20 p.m. PT
Terranea Resort in Rancho Palos Verdes, CA

Live audio webcasts of the presentations will be available by visiting the Investors section of the Atara website at www.atarabio.com. Archived replays of the webcasts will be available on the Company’s website for 14 days following each presentation.

On May 29, 2018 PharmaMar (MSE:PHM) has reported that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre (lurbinectedin, PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without any changes (Press release, PharmaMar, MAY 29, 2018, View Source [SID1234527441]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The IDMC’s recommendation came after an analysis of the safety data obtained with more than 500 patients treated in the trial. This pivotal randomized Phase III trial assesses the efficacy of PM1183 in combination compared with the standard treatment for this indication: investigator’s choice of either Topotecan or CAV (cyclophosphamide, doxorubicin, and vincristine).

About Zepsyre
Zepsyre (lurbinectedin, PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

About small-cell lung cancer
SCLC is a very aggressive cancer that usually presents with distant metastases and has already spread at the time of diagnosis, thus limiting the role of traditional approaches and posing a worse prognosis compared to other lung cancer types. The 5-year survival rate is about 5%i

About 18% of all the lung
cancer cases diagnosed are SCLC, and only in the US more than 34,000 new cases are recorded every year. This tumor is strongly associated with tobacco smoking, posing an important public health problemii.

After failure to treatment with a platinum-based therapy in first line, the therapeutic alternatives are very limited, and the approval of the last drug for this disease took place 20 years ago.

On May 29, 2018 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, reported that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 39th Annual Global Healthcare Conferenceon Tuesday, June 12, 2018at 8:40 am PT at the Terranea Resort, in Rancho Palos Verdes, CA (Press release, Arcus Biosciences, MAY 29, 2018, View Source [SID1234526921]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Individuals may access the live audio webcast by visiting the "Events & Presentations" section of the Company’s website at View Source A replay of the webcast will be available for 30 days following the live event.

Surface Oncology has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Surface Oncology, 2018, MAY 29, 2018, View Source [SID1234527480]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 29, 2018 Genmab A/S (Nasdaq Copenhagen: GEN) reported that its CEO, Jan van de Winkel, Ph.D., will present a company update at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, California at 4:00 PM PDT on June 12, 2018 (1:00 AM CEST on June 13, 2018) (Press release, Genmab, MAY 29, 2018, View Source [SID1234527080]). A webcast of the presentation will be available on Genmab’s website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!